Capital Investment Advisory Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Capital Investment Advisory Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100	Closed	-$5.42K	–	1174
2025 Q3	$5.42K	Hold	100	–	–	﹤0.01%	1008
2025 Q2	$5.5K	Buy	+100	New	+$5.89K	﹤0.01%	984
2019 Q4	–	Sell	-43	Closed	-$3K	–	632
2019 Q3	$3K	Hold	43	–	–	﹤0.01%	1198
2019 Q2	$4K	Hold	43	–	–	﹤0.01%	1165
2019 Q1	$4K	Hold	43	–	–	﹤0.01%	1003
2018 Q4	$4K	Buy	+43	New	+$4.09K	﹤0.01%	958

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Capital Investment Advisory Services's BMRN Position: Q4 2025 in Review

Capital Investment Advisory Services sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 100 shares — an estimated $5.42K sold.

Capital Investment Advisory Services first reported a position in BMRN in Q4 2018 and held it in 6 quarters. The position peaked at $5.5K in Q2 2025. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Capital Investment Advisory Services reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Capital Investment Advisory Services sold 100 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $5.42K.
Capital Investment Advisory Services first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 6 quarters.
Capital Investment Advisory Services's BioMarin Pharmaceuticals position peaked at $5.5K in Q2 2025.
540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Capital Investment Advisory Services's 13F filing for Q4 2025, filed 21 Jan 2026.